Progress driving change for a healthier and more inclusive future was evident at Reuters Pharma & Patient USA in Boston the other week. #REPatientUSA While “patient centered”, “patient focused”, and “patient driven” are hot terms in the life sciences industry, the processes and capabilities needed to collaborate with patient communities, generate insights, and develop solutions to drive better health outcomes, quality of life and longevity, remain immature and siloed. Truly integrating patient voices in biomedical research, clinical development, and along the entire regulatory approval and commercialization pathway is challenging for many organizations. This is because functions including patient advocacy, marketing, insights & analytics, medical affairs, patient experience, public affairs, CSR and others interpret and operationalize patient engagement differently. As an industry that conventionally regards patients as research subjects, there is a lot of work to do! 🙏 Here are some highlights from just a few of the speakers who are championing progress in their organizations and sharing learnings: Jon Zwinski of Chiesi USA, Inc. on being a B corp “we care about our social impact and we put patient impact on the same level as profitability” Negelle Morris of Novo Nordisk “The way we embed a diverse lens on culture and how people of different cultures engage with these diseases is essential” and “We measure success by the number of patients we serve” Desiree Priestley of Otsuka Pharmaceutical Companies (U.S.) “Technology alone cannot solve all the issues out there, high touch is necessary” Faye Feller of Geron Corporation “We have a debt to patients who supported us in clinical trials” and “There is a disconnect between the literature and the data we have gathered over the years which doesn’t align with the way we look at populations now” Monique G., Lupus patient advocate “Individuals who call themselves patients are equal stakeholders” Carla Tardif, Family Reach “We need to make financial health a part of the standard of care” Amy Akers Teets, Sanofi on shifting from talking about patient centricity, to “integrated patient engagement" and building an “actionable cycle of patient insights along the entire value chain” Inder Singh, Takeda Oncology on the expanded role of insights and analytics and “connecting the dots” Carmen White, Pfizer on what it takes to connect with and serve under-represented patients #patientengagement #pharma #patientvoice #actionableinsights
Such meaningful conversations. Thanks for highlighting.
Love this!
Global Head Patient Strategy, Specialty Care
4wThank you for the recognition along with so many great leaders. It will take us all working together and learning from one another to drive true change.